Estrogen and C-reactive protein: does an alternate route lead to a more attractive destination?
Duvernoy
Claire
C
D000279:Administration, Cutaneous; D000284:Administration, Oral; D002097:C-Reactive Protein / Q000032:analysis / Q000096:biosynthesis*; D003327:Coronary Disease / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D004958:Estradiol / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D015850:Interleukin-6 / Q000097:blood; D008875:Middle Aged; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D019851:Thrombophilia / Q000097:blood / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D002097:C-Reactive Protein